The PTEN (phosphatase and tensin homolog) phosphatase is unique in mammals in terms of its tumor suppressor activity, exerted by dephosphorylation of the lipid second messenger PIP 3 (phosphatidylinositol 3,4,5-trisphosphate), which activates the phosphoinositide 3-kinase/Akt/mTOR (mammalian target of rapamycin) oncogenic pathway. Loss-of-function mutations in the PTEN gene are frequent in human cancer and in the germline of patients with PTEN hamartoma tumor-related syndromes (PHTSs). In addition, PTEN is mutated in patients with autism spectrum disorders (ASDs), although no functional information on these mutations is available. Here, we report a comprehensive in vivo functional analysis of human PTEN using a heterologous yeast reconstitution system. Ala-scanning mutagenesis at the catalytic loops of PTEN outlined the critical role of residues within the P-catalytic loop for PIP 3 phosphatase activity in vivo. PTEN mutations that mimic the P-catalytic loop of mammalian PTEN-like proteins (TPTE, TPIP, tensins and auxilins) affected PTEN function variably, whereas tumor-or PHTS-associated mutations targeting the PTEN P-loop produced complete loss of function. Conversely, Ala-substitutions, as well as tumor-related mutations at the WPD-and TI-catalytic loops, displayed partial activity in many cases. Interestingly, a tumor-related D92N mutation was partially active, supporting the notion that the PTEN Asp92 residue might not function as the catalytic general acid. The analysis of a panel of ASD-associated hereditary PTEN mutations revealed that most of them did not substantially abrogate PTEN activity in vivo, whereas most of PHTS-associated mutations did. Our findings reveal distinctive functional patterns among PTEN mutations found in tumors and in the germline of PHTS and ASD patients, which could be relevant for therapy.
INTRODUCTION
PTEN (phosphatase and tensin homolog deleted in chromosome 10) is a mammalian lipid and protein phosphatase with orthologs in lower animals, plants and fungi (1) . In mammals, PTEN-related proteins exist whose activity has been poorly explored. These proteins include TPIP and TPTE (orthologs of a voltage-sensor phosphatase from Ciona intestinalis), as well as the actin-binding tensin 1/2/3 and the clathrin-binding auxilin 1/2 (2 -4) . PTEN most relevant function is based on its ability to dephosphorylate phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) in the 3 ′ phosphate of the inositol ring, resulting in the bisphosphate product phosphatidylinositol 4,5-bisphosphate (PIP 2 ), thus broadly inhibiting the oncogenic phosphoinositide 3-kinase (PI3K)-dependent signaling (5 -8) . As a tumor suppressor, PTEN exerts its function by counteracting the anti-apoptotic and growth stimulatory effects of PDK1 (phosphoinositidedependent kinase) and protein kinase B (PKB/Akt), which rely on PIP 3 for their activation (9, 10) . For Permissions, please email: journals.permissions@oup.com mutations in PTEN make this tumor suppressor gene one of the two most frequently affected in human malignancies, together with p53, especially in solid tumors (11) (12) (13) (14) . Germline mutations of PTEN lead to inherited hamartoma, Cowden syndrome and related disorders, generally known as PTEN hamartoma tumor-related syndromes (PHTSs) (15 -17) . PTEN is considered haploinsufficient to prevent certain malignancies, suggesting that dosage is important for its function, as it must be the influence of a given point mutation in the catalytic activity of the enzyme (18) . Besides its clear involvement in PHTS, germline PTEN mutations have been described in patients with neurodevelopmental disorders, such as autism spectrum disorders (ASDs) and developmental delay (DD) (19) (20) (21) (22) . Oncogenic PTEN mutations have been generally related to a loss of function of the encoded phosphatase. However, few studies have been done to understand the influence of putative neurodevelopment-related PTEN mutations on its catalytic activity.
Although phosphatase-independent functions of PTEN have also been described to contribute to its tumor suppressive activity (8, (23) (24) (25) , buffering PI3K signaling in virtue of its catalytic activity is assumed to be its key role. Thus, the precise dissection of PTEN catalytic properties is highly relevant for human disease. The crystal structure of PTEN (26) revealed an active site pocket similar to those of protein tyrosine phosphatases (PTPs) and dual-specificity Thr/Ser/Tyr phosphatases, as predicted by primary sequence analyses, although richer in basic residues. This explained the ability of PTEN to dephosphorylate acidic phosphopeptides (27) . In addition, the PTEN active site pocket was wider than that of PTPs, to accommodate the rather bulky phosphorylated inositol moiety that constitutes the polar head of PIP 3 (26) . The PTEN phosphatase signature motif ([123]HCKAGKGR[130]; P-loop), including the catalytic Cys124 and Arg130 residues, is located at the bottom of the active site pocket. The walls of the pocket are delimited in part by a WPD-loop (thus designed after the equivalent region in PTP1B) and a TI-loop (so named because of conserved Thr and Ile residues), which are thought to be important for the activity of the enzyme. The fact that the Asp92, within the PTEN WPD-loop, is located in the pocket in an identical fashion to the equivalent proton donor catalytic residue on PTP1B led to the hypothesis that it may serve as the general acid that allows protonation of the leaving phosphate during the dephosphorylation reaction. Although in vitro studies using an Asp92 to Ala PTEN mutation indicated that Asp92 does not act as the general acid (28, 29) , no conclusive studies have been done to analyze the contribution of Asp92 in the in vivo dephosphorylation of PIP 3 by PTEN.
We have previously validated a humanized yeast model to study the function of PI3K and PTEN in vivo, based on the heterologous co-expression of these proteins (1, 30, 31) . Briefly, expression of hyperactive p110a, the catalytic subunit of mammalian class I PI3K, results in high toxicity in yeast cells as a result of the depletion of essential PIP 2 pools. Co-expression of PTEN restores PIP 2 levels and suppresses PI3K toxicity. Besides, co-expression of GFP-tagged mammalian Akt in this system allowed the detection of pools of PI3K-generated PIP 3 in the yeast cell, where Akt localized, providing a visual readout of PI3K and PTEN activities (30, 32) . Here, we present an extensive site-directed mutagenesis and functional study of PTEN by using this system. Humanized yeast-based bioassays combine the advantages of powerful yeast genetics, an ever-growing availability of post-genomic tools, their ease and safety of manipulation and the fast achievement of results (1). Our results offer insights into the catalytic properties of PTEN and provide a platform to compare in vivo the contribution to lipid phosphatase inactivation of mutations found in tumors and in the germline of patients with PTEN-related syndromes. Our analysis reveals that PTEN germline mutations found in patients with ASD/DD neurodevelopmental disorders do not generally confer complete loss of function of the PTEN PIP 3 phosphatase activity, when compared with mutations found in the germline of PHTS patients with tumor disorders.
RESULTS

Ala-scanning of the catalytic loops at the PTEN active site
The PIP 3 lipid phosphatase activity of PTEN is essential for its tumor suppressor activity, which is evidenced by the abundance of tumor-related mutations in exons encoding the catalytic phosphatase core of the enzyme (11, 15, 33) . Thus, the precise definition of PIP 3 catalytic properties of PTEN in vivo, and its relation with PTEN residues mutated in tumor samples or in patients, is highly relevant in oncology. The PTEN active site is conformed by three catalytic loops (26) : the WPD-loop, residues 88-98; the P-loop, residues 121-131; and the TI-loop, residues 160-171 (Fig. 1A) . The P-catalytic loop (containing the essential catalytic cysteine; Cys124 in human PTEN) is highly conserved between species, from mammals to lower eukaryotes, whereas the WPD-and TI-loops are more divergent (Fig. 1B) . To test the contribution of all individual residues within the three PTEN catalytic loops to the in vivo activity of the enzyme, a comprehensive Ala-scanning mutagenesis was performed. The PIP 3 catalytic activity of the resulting mutations was assessed in vivo using a reconstitution heterologous system in the yeast Saccharomyces cerevisiae (31) . As illustrated in Figure 2 , Ala substitutions of the residues at the core P-loop (residues 121-131) substantially abrogated the PTEN ability to dephosphorylate PIP 3 in vivo, with the exception of the A121V, G129A and T131A mutations, which displayed partial or total activity (note that Ala residues have been substituted by Val residues in our Ala-scanning mutational analysis). Remarkably, a Cowden disease mutation targeting the Gly129 residue (G129E) is defective for PIP 3 phosphatase activity but maintains in vitro activity against phosphotyrosine peptides (34) . Overall, the residues at the WPD-and TI-loops were less important for PIP 3 catalytic activity. Thus, Ala substitutions of most WPD residues (88 -98) did not affect, or only partially affected, PTEN catalytic activity, with the exception of Asp92 and His93 that fully abrogated the PTEN function (Fig. 2) . Also, Ala substitutions of most TI residues (160 -171) only weakly affected the PTEN activity, except for Val166, Gln171 and, to some extent, Asp162. (Fig. 2) The loss-of-function properties of the D92A mutation is in accordance with the importance of this residue in PTEN Human Molecular Genetics, 2011, Vol. 20, No. 21 4133 phosphatase catalysis, although its role as the general acid in the hydrolysis reaction remains unclear (28, 29) .
Functional analysis of mutations at the PTEN P-loop mimicking PTEN-like proteins PTEN-like proteins include TPIP and TPTE, as well as tensins and auxilins. The WPD-and TI-loops are divergent between PTEN and PTEN-like proteins, whereas the P-loop is more conserved (Fig. 1C ). As part of our mutational analysis of the PTEN active site, we designed single amino acid substitution mutants on PTEN that mimicked the P-loop from the different PTEN-like proteins and tested their PIP 3 phosphatase activity in the yeast system. Mutations included A121V, I122L, I122V, H123Y, C124N, K125L, K125M, K125R, A126D, A126G, G127N, K128R, K128T, G129D, G129A, R130A, R130K, T131I, T131L and T131S (note that A121V, G129A and R130A mutations are included in Fig. 2 ). A group of mutations (H123Y, C124N, A126D, G127N, K128T, G129D, R130A, R130K, T131I and T131L) fully abrogated the PIP 3 phosphatase activity of PTEN in yeast, whereas other two groups only affected partially (I122L, K125L, K125M, A126G and K128R) or did not affect PTEN PIP 3 phosphatase activity (A121V, I122V, K125R, G129A and T131S) ( Fig. 3 ; note that results for A121V, G129A and R130A mutations are included in Fig. 2 ). The results from this mutational analysis are in agreement with the in vitro PIP 3 phosphatase activity reported for TPIP and with the lack of activity reported for TPTE (35) . Our results also suggest that the P-loops from tensin and auxilin proteins do not bear catalytic activity. Moreover, this analysis revealed that some conservative mutations at the PTEN P-loop (such as I122V, K125R and T131S) are permissive for its activity in vivo.
Functional analysis of tumor-related mutations targeting PTEN active site residues
Tumor-related mutations are spread along the entire PTEN amino acid sequence. Nevertheless, the PTEN C-terminal tail (last 50 residues) is targeted by mutations less frequently, in agreement with our previous finding using the yeast heterologous system that PTEN 1 -349 is the minimal fully functional PTEN protein (30) . On the other hand, the core PTP catalytic domain (residues 14-185) is more frequently targeted by mutations in either tumors or PHTS patients. Some of these mutations have been analyzed in terms of intrinsic catalytic activity (36) (37) (38) (39) (40) , but the majority of them have not been directly tested for function. We have analyzed in the yeast system the PIP 3 phosphatase activity of tumor-related mutations targeting PTEN residues at the PTEN catalytic loops (note that some of these mutations have been analyzed previously and are shown in Figs 2 and 3; and Figs 5 and 6 also include some of them). As expected, all the tumor mutations at the P-loop tested (A121E, I122S, H123D, H123Y, C124S, K125E, A126S, A126V, G127E, K128N, G129E, G129V, G129R, R130G, T131A and T131I) gave rise to proteins that were fully inactive, except for A126S and K128N that produced partially inactive proteins ( Fig. 4 and Figs 2 and 3). Mutations at the TI-loop included T160I, R161G, D162G, G165E, G165V, V166I, T167A, I168F, P169H and S170R. Among these, only the T160I, G165E, G165V and S170R were loss-of-function mutations ( Fig. 4 and Fig. 2 ). Finally, tumor-related mutations targeting the WPD loop included Y88C, F90L, E91A, D92A, D92E, D92G, D92H, D92N, D92V, H93D, H93Q, H93R, H93Y, N94I, P95L and P96Q. Proteins bearing Y88C, F90L or E91A mutations were active, whereas the rest of mutant proteins were partially or fully inactive ( Supplementary Material, Table S1 . Taken together, our findings illustrate the heterogeneity in the catalytic activity of tumor-related PTEN mutant proteins.
Relevance of the Asp92 residue in PTEN activity in vivo
Remarkably, a mutation in the putative catalytic Asp92 residue to Asn (D92N) rendered a protein partially active in vivo in the yeast system, whereas substitution of this residue to any of the other 18 amino acids generated fully inactive PTEN enzymes (Fig. 5A) . This outlines the importance of Asp92 in PTEN enzymatic activity, but also demonstrates that the presence of an aspartic acid residue at this position is not a strict requirement for PTEN-driven catalysis. To further substantiate this observation, the PIP 3 phosphatase activity of the PTEN mutations D92A (non-conservative), D92E (charge-conservative) and D92N (size-conservative), expressed in mammalian cells, was tested both in vitro and in vivo. As shown, the mutations D92A and D92E fully abrogated hydrolysis of PIP 3 by PTEN in vitro, whereas the mutation D92N only partially affected it (Fig. 5B) . Upon co-expression with Akt, the D92N PTEN mutant also manifested more activity [indirectly measured as the levels of phospho-Akt (p-Akt) content] than the D92A or the D92E mutant proteins (Fig. 5C ). Our results suggest that Asp92 does not behave as the general acid in the hydrolysis of PIP 3 by PTEN, in vitro and in vivo.
Most of germline PTEN mutations associated with autism syndrome disorders do not fully abrogate PIP 3 phosphatase activity
The involvement of PTEN in brain developmental disorders has been proposed on the basis of the identification of hereditary PTEN mutations in patients with these disorders (41, 42) , but little information is available on the severity of such mutations in terms of PTEN function. One of the mutations present in glioblastoma tumor samples (H93R) has also been found in the germline of a patient with autism (19) . When performing the experiments shown above on tumor-related PTEN mutations, we included the H93R and found it to display a modest loss of activity in the yeast model when compared with wild-type PTEN, although it was capable of fully recovering yeast growth (Fig. 6B ). This prompted us to examine additional inherited mutations found in patients with autismrelated disorders (ASD) or with DD/mental retardation. These mutations included, besides H93R, the G44D, H118P, H123Q, M134T, E157G, R173H, Y176C, T202I, F241S, D252G, W274L, N276S and D326N, involving not only catalytic but other protein domains. Remarkably, proteins bearing most of these mutations were either fully or partially active in the yeast (Fig. 6B and Supplementary Material, Table S1 ), although their ability to recover growth from PI3K-imposed inhibition was variable. These results were in contrast to those obtained by analyzing the function of a panel of PHTS-associated mutations, also distributed along the entire PTEN coding region (mutations A34D, M35R, G36R,  N48K, H61D, Y68D, D92E, H93Y, P96Q, H123D, C124S,  G129E, R130G, Y155C, G165E, G165V, S170R, L181P,  V217N, Table S1 ). Most of the PHTS-associated mutations generated total or partial loss of function when analyzed in vivo in yeast. Moreover, global comparison of PHTS-and ASD/DD-related mutations in terms of their ability both to deplete PIP 3 generated by PI3K in yeast ( Fig. 6C ; P , 0.001) and to rescue yeast growth (Fig. 6D) revealed that ASD/DD-related PTEN mutations have a lower effect in PTEN activity than those associated with PHTS. These findings indicate that specific PTEN functional patterns correlate with the mutations found on either PHTS or ASD/DD patients and suggest that a severe loss of the PTEN PIP 3 catalytic activity may not be the major driver of autism or autism-related neurological disorders.
DISCUSSION
The PTEN phosphatase is a key regulatory hub of PI3K-mediated signaling. While mammals express a variety of isoforms of PI3K and PIP 3 -dependent downstream kinases in this pathway, the PTEN tumor suppressor is rather unique, being the only one gene that encodes for a common inactivator of the pathway. Thus, mutations in exons of the PTEN gene are frequent in tumors and hereditary cancer syndromes. The regulation of PTEN is complex, involving multiple processes related to its phosphorylation, ubiquitination, nuclear translocation, interaction with membranes and complexing with different proteins (6, 8, 24, 43, 44) . Although recent reports point towards PTEN functions independent of its lipid phosphatase activity (23) (24) (25) 45, 46) , PTEN tumor suppressor function mainly relies on its catalytic activity on PIP 3 pools locally generated by PI3K at the plasma membrane. The contribution of PTEN mutations isolated in the clinics to the function of the encoded protein is crucial to understand the molecular mechanisms that lead to tumor development and progression. We have developed a simple model for functional assessment of PTEN mutations based on heterologous expression in yeast (1, 31) . This model allows ready evaluation of the involvement of PTEN mutations on the ability to counteract PI3K activity in vivo, by compromising PTEN PIP 3 catalytic activity or by affecting PTEN protein stability, two common mechanisms by which PTEN is inactivated in tumors (30) . Here, we report extensive use of this model with two aims: (i) to provide clues for structure -function relationship by systematic mutagenesis and (ii) to study the influence of individual disease-related PTEN mutations in its lipid phosphatase activity.
From our systematic functional analysis on the PTEN catalytic loops, several conclusions can be driven. First, as expected, the P-loop including the catalytic Cys residue is very sensitive to mutagenesis, in consonance with the observation that it constitutes a hot spot for tumor-related mutations (11, 15, 33) , whereas the WPD and TI loops are more permissive to point Ala substitutions. Still, residues like Asp92 or His93 (WPD-loop), Asp162, Val166 or Gln171 (TI-loop) were critical for function. We made a comprehensive study on tolerance to mutation of the Asp92 residue, equivalent to the acid proton donor involved in catalysis in PTPs that are Figure 2 . The alignment marks divergences within the P-loop sequence between PTEN and PTEN-related proteins, which correspond to the substitutions made in the PTEN-mutated versions. The numbering of residues for PTEN is shown. '¼' indicates the same residue at that position than PTEN. The data for substitutions marked in italics in this alignment are already presented in Figure 2 . The asterisk marks a mutation reported in tumors/germline PHTS.
4136
Human Molecular Genetics, 2011, Vol. 20, No. 21 structurally related to PTEN (47) . Tolerance to mutation was very low in this residue, since its substitution to any other amino acid yielded an inactive enzyme, except for Asp-to-Asn substitution, which partially retained activity in vivo, not only in the yeast model but also in mammalian cells. Since the D92N mutation has been reported in the clinic, such reduced activity may substantially contribute to disease. Interestingly, this argues against the need for an acid residue in that position, revealing an alternative mechanism of catalysis for the PTEN phosphatase, as proposed by other authors based on in vitro experiments (28, 29) . We also made substitutions within the catalytic loops mimicking PTEN-related proteins, such as TPIP, TPTE, tensin and auxilin. Although these proteins possess distinct non-PTP-related domains that control protein targeting, protein -protein interactions and cell signaling, they share the presence of PTP-and C2-like domains with significant similarity with those from PTEN (2, 3, 48) . With the exception of TPIP, PTEN-like proteins are predicted to be catalytically inactive, due either to the lack of essential residues at the catalytic site or to amino acid substitutions potentially deleterious for catalysis (35, 49, 50) . Nevertheless, tensin2/C1-TEN has been proposed to be an active phosphatase, based on functional studies on a mutation that targets its putative catalytic cysteine residue (51). Our observations favor the hypothesis that the P-loop of TPIP might be competent for activity, whereas TPTE, tensins and auxilins would be inactive as phosphatases, as evidenced in other studies (35, 52, 53) . A large number of different PTEN mutations have been described in human tumors and in the germline of patients with PHTS or PHTS-related syndromes (11, 15, 33) [for updates, check HGMD (http://www.hgmd.cf.ac.uk/ac/index.p hp) and COSMIC (http://www.sanger.ac.uk/genetics/CGP/ cosmic) databases]. These mutations target the PTEN gene not only at its coding regions, but also at exon -intron boundaries and promoter regions. Most of PTEN mutations at exonintron boundaries or promoter regions have a major impact in the levels of expression of the PTEN protein, being causative of PTEN functional deficiency and considered as pathogenic (54) (55) (56) . Mutations targeting the PTEN coding region include frame-shift and nonsense mutations, which also generate unstable truncated PTEN proteins in most of the cases (36), as well as missense mutations that result in individual amino acid changes. Functional analyses of a limited number of these missense mutations have revealed that, in many cases, the resultant amino acid substitutions generate PTEN proteins with impaired intrinsic catalytic activity and/or protein stability (36) (37) (38) (39) . Also, some examples have been described of missense PTEN mutations that do not affect the intrinsic catalysis nor the stability of the protein, but rather impair essential regulatory PTEN properties, such as binding to membranes or nuclear entry (40, 57) . Our previous study using the heterologous yeast system as a reporter of the activity of PTEN mutations in vivo revealed that such system reproduces with fidelity the effects on mammalian cells of mutations that diminish either the intrinsic PTEN catalytic activity and/or binding to membranes or the intrinsic PTEN protein stability (30) . Our current comprehensive functional study of tumor-associated PTEN mutations indicates that almost all mutations targeting the P-catalytic loop confer loss of PTEN intrinsic catalytic activity (12 of 13), whereas mutations targeting the WPD-or the TI-loops are less frequently associated with full loss of catalysis (5 of 9 and 4 of 9, respectively). These results are in agreement with the Ala-scanning analysis of these regions and suggest the existence of a relatively large number of tumorassociated mutations at the PTEN gene that do not fully abrogate the PTEN catalytic activity, but may be relevant in clinics. Recently, a comprehensive study on PTEN mutations in PHTS disease has yielded predictive clinical parameters (58) . Association of reported mutations to the activity of PTEN by means of ready in vivo functional assays, as the one exploited here, might help clinicians in decisions towards putative mutation-specific therapies.
PHTS and ASD/DD are syndromes with distinct clinical entities, which share macrocephaly as a frequent common alteration (59) . Also, clinicians have noted that PHTS patients often display neurobehavioral features resembling autism (19) and, interestingly, at least five PTEN mutations (H93R, Y176C, F241S, D252G and R173H; see Supplementary Material, Table S1 ) have been reported as associated with both PHTS and ASD/DD (19, 41, 42, 58) . Our comparative analysis of germline mutations found in PHTS patients and in ASD/DD patients revealed a distinct functional pattern for these two groups of mutations. PHTS-associated mutations, Human
which included in our study mutations distributed all along the PTEN protein, were found significantly more deleterious for PTEN catalysis than ASD/DD-associated mutations (Fig. 6 ). This could be important for the distinct etiology and progress of tumor-related and tumor non-related syndromes associated with PTEN mutations and may be of relevance in the design and implementation of new therapies for these diseases. It is likely that small variations in the lipid phosphatase activity or in the stability of heterozygotic PTEN mutations can explain the higher penetrance found for the set of PHTS-associated mutations, when compared with ASD/ DD-associated mutations. Although it has been suggested that ASD-and macrocephaly-related PTEN mutations may behave differentially in terms of loss of function (19) , the lack of functional models has made difficult to provide support for this hypothesis. If this is the case, as suggested by our study, additional unknown factors might exist affecting differentially the etiology and/or progression of these diseases.
In this regard, a study focused on the functional analysis of the PHTS-and ASD-associated H93R PTEN mutation reported a partial loss of catalytic activity for this mutation, as well as a defect in the binding to PTEN-activating PIP 2 model membranes. Remarkably, the binding of the H93R mutation to phosphatidylserine membranes, which are abundant in mammalian cells, was augmented (60) . Our results show that the H93R mutation retained most of its lipid phosphatase activity in the yeast, suggesting that differences in the thresholds that control membrane-binding mediated PTEN activation may exist in distinct cell systems. Also of interest, mice with diminution of PTEN expression levels as subtle as 20% develop a wide spectrum of tumors with high penetrance, and it has been proposed that altered gene dosage may be relevant in ASD/DD (18, 61) . In this regard, ASD/DD has been linked with abnormal synapsis growth and plasticity, an alteration that has also been observed in mice with PTEN-deficient neurons (62, 63) . Furthermore, a mice model lacking PTEN expression in mature neuronal populations in the cerebral cortex and the hippocampus displayed behavioral abnormalities reminiscent of human ASD/DD (64) . Our findings show a relatively weak association between ASD/DD-related mutations at the PTEN gene and full loss of intrinsic lipid phosphatase activity or protein stability, which is in line with the lack of concordance between ASD/DD and childhood cancer (65) . ASD/DD constitutes a heterogeneous, multigene-linked group of developmental disorders (41, 42, 66) . Further studies will be required to ascertain the functional changes on the activity of the PTEN protein from ASD/DD patients with mutations at the PTEN gene. The comprehensive analysis of the functional properties of putative pathogenic mutant proteins, as the one we present here for PTEN mutations, will give some light on the molecular pathways altered in the neurons of patients with ASD/DD.
MATERIALS AND METHODS
Cells, media, growth conditions, transfection and protein detection
The S. cerevisiae strain YPH499 (MATa ade2 -101 trp1 -63 leu2-1 ura3 -52 his3-△200 lys2 -801) was used for heterologous expression of mammalian proteins. For all the analyses, . Each spot corresponds to the average data from three independent experiments on each particular mutation from the indicated category (PHTS or ASD/DD). Spots surrounded by a circle correspond to mutations that are common to PHTS or ASD/DD [those marked with asterisks in (B)]. Vertical lines mark the standard deviation. Paired t-test of these independent set of data revealed a significant difference in activity for ASD/DD mutations with respect to PHTS mutations (P , 0.001). (D) Comparative analysis of PHTS and ASD/DD PTEN mutations referred to their ability to rescue growth arrest induced in S. cerevisiae by p110a-CAAX expression. ASD/DD-related mutations are generally more competent than PHTS-related mutations in counteracting p110a-CAAX activity. PHTS mutations included in this study are listed in Supplementary Material, Table S1 , and results correspond to those in (A) and in Figures 4 and 5 . ASD/DD mutations data correspond to those in (B).
Human Molecular Genetics, 2011, Vol. 20, No. 21 4139 SD lacking uracile, leucine or both (SD-U, SD-L or SD-UL) as required and adjusted to an OD 600 of 0.5. Five microliter aliquots of each sample plus three serial 1/10 dilutions were deposited on the surfaces of solid media SG-U, SG-L or SG-UL. Growth was monitored after 2-3 days at 308C. Expression of all PTEN mutations in yeast was verified by immunoblot on yeast lysates with 421B or 425A anti-PTEN mAb (67) followed by horseradish-peroxidase-conjugated anti-mouse antibody (Calbiochem). To measure GFP-Akt1 plasma membrane localization, as an indirect indicator of cellular PIP 3 levels, transformant cells were grown to log phase in liquid SR medium lacking the corresponding auxotrophic markers, and then 2 % galactose was added for 6 -8 h. GFP-Akt1 was visualized by fluorescence microscopy. To obtain statistically significant data, ≥100 cells were examined from each condition or experiment for either cytoplasmic or membrane-associated localization. Cells were examined under an Eclipse TE2000U microscope (Nikon) and digital images were acquired with Orca C4742-95-12ER chargecoupled device camera (Hamamatsu) and Aquacosmos Imaging Systems or HCImage software. To overexpress PTEN mutations in mammalian cells, COS-7 cells (simian kidney) were transfected by the DEAE-dextran method and processed after 48 h. To measure p-Akt content in COS-7 cells in the presence of PTEN mutations, cells were co-transfected with pRK5 PTEN and pSG5 HA-Akt1 as described (68) . Cells were lysed, and post-nuclear lysates were subjected by immunoblot using a mixture of anti-p-Thr308 and anti-p-Ser473-Akt antibodies (Cell Signalling Technologies). Membranes were stripped and probed for anti-Akt antibody (Cell Signalling Technologies). Bands were quantified using ImageQuant TL software, and results are represented as the average + SD of the p-Akt/Akt ratio.
Plasmids, mutagenesis and in vitro phosphatase assays. YCpLG myc-p110-CAAX, pYES2 PTEN, pRK5 PTEN, pSG5 HA-Akt1 and pYES3 GFP-Akt1 have been described previously (30) . Mutagenesis was performed by a two-step PCR strategy. All mutations were checked by DNA sequencing. The sequences of oligonucleotides used for mutagenesis are available on request. In vitro phosphatase assays were made using PTEN wild-type or mutations, from COS-7-transfected cells, as the enzymes, and diC8-phosphatydilinositol PIP 3 (Echelon) as the substrate, as described previously (30) .
